GCM
NGM

Graham Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Graham Capital Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-32,643
Closed -$133K – 1381
2023
Q1 		$133K Sell
32,643
-80,134
-71% -$370K ﹤0.01% 989
2022
Q4 		$566K Buy
+112,777
New +$707K 0.02% 731
2022
Q3 		– Sell
-12,492
Closed -$160K – 1377
2022
Q2 		$160K Buy
+12,492
New +$173K 0.01% 940

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Graham Capital Management's NGM Position: Q2 2023 in Review

Graham Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 32,643 shares — an estimated $133K sold.

Graham Capital Management first reported a position in NGM in Q2 2022 and held it in 3 quarters. The position peaked at $566K in Q4 2022. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

  • Graham Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Graham Capital Management sold 32,643 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $133K.
  • Graham Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Graham Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $566K in Q4 2022.
  • 106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Graham Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.